SLE - Rituximab in lupus
B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled tr...
Tallennettuna:
| Julkaisussa: | Arthritis Res Ther |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMC
2003
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC165056/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12823844/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/ar759 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|